APA

Glintborg B., Kringelbach T., Bolstad N., Warren D. J., Eng G., Sørensen I. J., Loft A. G., Hendricks O., Hansen I., Linauskas A., Nordin H., Kristensen S., Lindegaard H., Jensen D. V., Goll G. L., Høgdall E., Gehin J., Enevold C., Nielsen C. H., Krogh N. S., Johansen J. S. & Hetland M. L. (20180924). Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. : Scandinavian journal of rheumatology.

Chicago

Glintborg B, Kringelbach T, Bolstad N, Warren D J, Eng G, Sørensen I J, Loft A G, Hendricks O, Hansen Imj, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen D V, Goll G L, Høgdall E, Gehin J, Enevold C, Nielsen C H, Krogh N S, Johansen J S and Hetland M L. 20180924. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. : Scandinavian journal of rheumatology.

Harvard

Glintborg B., Kringelbach T., Bolstad N., Warren D. J., Eng G., Sørensen I. J., Loft A. G., Hendricks O., Hansen I., Linauskas A., Nordin H., Kristensen S., Lindegaard H., Jensen D. V., Goll G. L., Høgdall E., Gehin J., Enevold C., Nielsen C. H., Krogh N. S., Johansen J. S. and Hetland M. L. (20180924). Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. : Scandinavian journal of rheumatology.

MLA

Glintborg B, Kringelbach T, Bolstad N, Warren D J, Eng G, Sørensen I J, Loft A G, Hendricks O, Hansen Imj, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen D V, Goll G L, Høgdall E, Gehin J, Enevold C, Nielsen C H, Krogh N S, Johansen J S and Hetland M L. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. : Scandinavian journal of rheumatology. 20180924.